Trial Profile
Feasibility study of CBDCA+TS-1 adjuvant therapy for p-stage IB(T2a>4cm)/II/IIIA non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Oct 2020
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 19 Oct 2020 Status changed from active, no longer recruiting to completed.
- 27 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 26 Oct 2012 New trial record